Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.78 |
| ▸ | RAB9A | P51151 | 7/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | GLA | P06280 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | CASP3 | P42574 | 1/20 | 0.71 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.71 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.71 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.71 |
| ▸ | PHGDH | O43175 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460399 | 0.88 | RAB9A (0.77) | NPC1RAB9AMAPK1SMN1; SMN2GAA | |
| SCHEMBL7292358 | 0.88 | NPC1 (1.00) | NPC1RAB9AMAPK1SMN1; SMN2GAA | |
| SCHEMBL15149597 | 0.87 | NPC1 (0.61) | NPC1RAB9AMAPK1SMN1; SMN2GAA | |
| SCHEMBL2342297 | 0.87 | NPC1 (0.77) | NPC1RAB9AMAPK1SMN1; SMN2GAA | |
| SCHEMBL27847056 | 0.85 | PHGDH (0.74) | NPC1RAB9AMAPK1SMN1; SMN2GAA | |
| SCHEMBL641989 | 0.85 | PHGDH (0.77) | NPC1RAB9AMAPK1SMN1; SMN2GAA | |
| SCHEMBL6958604 | 0.84 | PHGDH (0.76) | NPC1RAB9ASMN1; SMN2ALDH1A1PHGDH | |
| SCHEMBL2414416 | 0.83 | PHGDH (0.70) | NPC1RAB9AMAPK1SMN1; SMN2GAA | |
| SCHEMBL10376329 | 0.83 | PHGDH (0.70) | NPC1RAB9AMAPK1SMN1; SMN2GAA | |
| SCHEMBL7301496 | 0.82 | HTT (0.73) | NPC1RAB9AMAPK1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019045-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20030078431-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2003-04-24 | — | — | US | disclosed |
| US-6500851-B2 | ANTICOAGULANT IN MAMMLS | ELI LILLY AND COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-20020173518-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-11-21 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| EP-1019045-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6372759-B1 | BLOOD COAGULATION FACTOR XA FOR MAMMALS | ELI LILLY AND COMPANY | 2002-04-16 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-1019045-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999000128-A9 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 1999-08-05 | — | — | WO | disclosed |
| WO-1999000128-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
| EP-0358118-B1 | Phenylamides - process for their preparation as well as a drug containing those compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-16 | — | — | EP | disclosed |
| US-5135949-A | Anticoagulants | BOEHRINGER MANNHEIM GMBH (DE) | 1992-08-04 | — | — | US | disclosed |
| EP-0358118-A1 | Phenylamides - process for their preparation as well as a drug containing those compounds | Roche Diagnostics GmbH (DE) | 1990-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173518-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | NPC1 1604/4885RAB9A 3012/4885MAPK1 578/4885 |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | NPC1 1618/4885RAB9A 2658/4885MAPK1 1423/4885 |
| US-20030078431-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | NPC1 1604/4885RAB9A 3012/4885MAPK1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.